Sources Raizada, K., & Margolin, E
As noted above, in late 2023 the FDA moved 17 peptides popular among longevity enthusiasts BPC-157, TB-500, and others into Category 2, banning them from compounding, while a gray market of self-proclaimed RUO sellers continued operating behind disclaimers the FDA does not recognize for these products as they are being promoted
Common changes include facial volume loss, skin laxity, dryness, and injection site reactions
Everything comes housed in a sleek container that tucks away easily when not in use
One of the most common concerns for athletes, competitors, and professionals using BPC-157 is whether it shows up on a drug test especially in WADA-governed sports or jobs with strict testing protocols